https://www.dovepress.com/dual-role-for-a-mek-inhibitor-as-a-modulator-of-inflammation-and-host–peer-reviewed-article-COPD https://www.ncbi.nlm.nih.gov/pubmed/32063702?dopt=Abstract Dual Role For A MEK Inhibitor As A Modulator Of Inflammation And Host Defense Mechanisms With Potential Therapeutic Application In COPD. Related Articles Dual Role For A MEK Inhibitor As A Modulator Of Inflammation And Host Defense Mechanisms With Potential Therapeutic Application In COPD. Int J Chron Obstruct Pulmon Dis. 2019;14:2611-2624 Authors: Kurian […]
Int J Chron Obstruct Pulmon Dis
Mepolizumab in the treatment of eosinophilic chronic obstructive pulmonary disease
https://www.dovepress.com/mepolizumab-in-the-treatment-of-eosinophilic-chronic-obstructive-pulmo-peer-reviewed-fulltext-article-COPD https://www.ncbi.nlm.nih.gov/pubmed/31496677?dopt=Abstract Mepolizumab in the treatment of eosinophilic chronic obstructive pulmonary disease. Mepolizumab in the treatment of eosinophilic chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2019;14:1779-1787 Authors: Mkorombindo T, Dransfield MT Abstract Despite maximal medical therapy, a subset of patients with chronic obstructive pulmonary disease continue to suffer acute exacerbations. It is […]
Personalized medicine for patients with COPD: where are we?
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6636434/ https://www.ncbi.nlm.nih.gov/pubmed/31371934?dopt=Abstract Personalized medicine for patients with COPD: where are we? Related Articles Personalized medicine for patients with COPD: where are we? Int J Chron Obstruct Pulmon Dis. 2019;14:1465-1484 Authors: Franssen FM, Alter P, Bar N, Benedikter BJ, Iurato S, Maier D, Maxheim M, Roessler FK, Spruit MA, Vogelmeier CF, Wouters EF, Schmeck B Abstract […]
Extrafine triple therapy delays COPD clinically important deterioration vs ICS/LABA, LAMA, or LABA/LAMA
https://www.ncbi.nlm.nih.gov/pubmed/30880943?dopt=Abstract Extrafine triple therapy delays COPD clinically important deterioration vs ICS/LABA, LAMA, or LABA/LAMA. Extrafine triple therapy delays COPD clinically important deterioration vs ICS/LABA, LAMA, or LABA/LAMA. Int J Chron Obstruct Pulmon Dis. 2019;14:531-546 Authors: Singh D, Fabbri LM, Vezzoli S, Petruzzelli S, Papi A Abstract Background: Current pharmacological therapies for COPD improve quality of […]